This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Tungsten-Induced Denaturation and Aggregation of Epoetin Alfa During Primary Packaging as a Cause of Immunogenicity
Pharmaceutical Research Open Access 18 November 2011
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sharma, B. et al. Eur. J. Hosp. Pharm. 5, 86–91 (2004).
Ryan, M.H. et al. Int. Immunopharmacol. 6, 647–655 (2006).
Yano, K., Ohno, S., Nakajima, Y., Toyoshima, S. & Nakajin, S. J. Health Sci. 49, 195–204 (2003).
Boven, K. et al. Kidney Int. 67, 2346–2353 (2005).
NKF-K/DOQI. Am. J. Kidney Dis. 37 (1 Suppl 1), S182–S238 (2001).
Locatelli, F. et al. Nephrol. Dial. Transplant. 19 Suppl 2, ii1–47 (2004).
Rossert, J. et al. Nephrol. Dial. Transplant. 21 Suppl 4, iv153 (2006).
Tredree, R. & Pearce, S. Eur. J. Hosp. Pharm. 1, 11–15 (2003).
Wegewijs, H.W. Eur. J. Hosp. Pharm. 1, 15–17 (2003).
Crommelin, D.J.A., Bissig, M., Gouveia, W. & Tredree, R. Eur. J. Hosp. Pharm. 1, 17–22 (2003).
Boven, K. et al. Nephrol. Dial. Transplant. 20 Suppl 3, iii33–40 (2005).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sharma, B., Ryan, M. & Boven, K. Reactions to Eprex's adverse reactions. Nat Biotechnol 24, 1199–1200 (2006). https://doi.org/10.1038/nbt1006-1199
Issue Date:
DOI: https://doi.org/10.1038/nbt1006-1199
This article is cited by
-
Tungsten-Induced Denaturation and Aggregation of Epoetin Alfa During Primary Packaging as a Cause of Immunogenicity
Pharmaceutical Research (2012)
-
The FDA's assessment of follow-on protein products: a historical perspective
Nature Reviews Drug Discovery (2007)